Central retinal vein occlusion in the only functional eye: the effect of bevacizumab treatment
Abstract
Aim: Presentation of a group of a seven patients, who all developed central retinal vein occlusion (CRVO) in the only functional eye, and were treated with bevacizumab (Avastin®). Methods: The diagnosis was established on the basis of a significant clinical picture. Prior to the treatment, we determined visual acuity (ETDRS) and performed optic coherence tomography (OCT). All patients received three serial injections of bevacizumab (Avastin®) at monthly intervals. We evaluated the effect of the treatment every month, over a period of one year. In the case of persistent oedema in the macula, bevacizumab was injected again. Results: The visual acuity improved in all patients. A significant morphological change was observed: a reduction in the thickness of the central retina and the volume of the retina, as determined by OCT. Conclusions: The treatment of central retinal vein occlusion with bevacizumab (Avastin®) in patients with only one functional eye resulted in a good morphological and functional outcome. This may be partly due to the fact that patients with only one functional eye are much more sensitive to changes in visual acuity in that eye, and are much more likely to seek treatment earlier than would such patients with both functional eyes. Also, patients with one functional eye are more motivated to diligently monitor their cardiovascular risk factors than those with both functional eyes.Downloads
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
